

Erratum to: A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX[®]

J. A. Kanis · H. Johansson · A. Oden · E. V. McCloskey

Published online: 31 May 2011

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011

Erratum to: Osteoporos Int DOI 10.1007/s00198-010-1474-0

An error occurred in this publication due to the incorrect computation of the hazard ratio (HR) for the effects of strontium ranelate. Treatment with strontium ranelate was associated with a decrease in the risk of a clinical vertebral fracture compared with placebo (HR=0.75; 95% confidence interval 0.62–0.92). In the original publication the HR was given as 0.50 (95% CI 0.41–0.60). The error does not affect the overall interpretation of the data or conclusions but alters the numerical values given in Tables 3, 4, 5, 6. The corrected tables are given below.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00198-010-1474-0>.

J. A. Kanis (✉) · H. Johansson · A. Oden · E. V. McCloskey
WHO Collaborating Centre for Metabolic Bone Diseases,
University of Sheffield Medical School,
Beech Hill Road,
Sheffield S10 2RX South Yorkshire, UK
e-mail: w.j.Pontefract@shef.ac.uk

Table 3 The relationship of incident fracture (fractures/100 patient years) in placebo-treated patients by quartiles of fracture probability

Fracture outcome	Quartile			
	I	II	III	IV
Clinical fractures				
All clinical osteoporotic fractures	4.34	6.14	7.50	10.10
All clinical fractures	4.78	6.72	8.05	10.62
Non-vertebral OP fractures	2.97	3.43	5.36	5.72
All non-vertebral fractures	3.38	4.01	5.88	6.24
Hip fracture	0.33	0.62	1.32	1.82
Vertebral fractures				
Morphometric	4.68	5.60	6.56	9.41
Clinical vertebral fracture	1.56	2.76	2.41	4.74

Table 4 Overall effects of strontium ranelate compared to placebo according to the fracture outcome selected

Fracture outcome	HR	95% CI	<i>p</i>
Clinical fractures			
All	0.82	0.73–0.93	=0.0013
Osteoporotic	0.80	0.71–0.91	<0.001
Non-vertebral fractures			
All	0.87	0.75–1.00	=0.053
Osteoporotic	0.84	0.72–0.98	=0.028
Hip	0.95	0.70–1.28	>0.30
Vertebral fractures			
Clinical	0.75	0.62–0.92	=0.0044
Morphometric	0.60	0.52–0.69	<0.001

Table 5 Hazard ratio between treatments (strontium ranelate versus placebo) for all clinical osteoporotic fractures at different values of 10 year probability (%) of a major osteoporotic fracture calculated with and without BMD

Percentile	Probability calculated without BMD			Probability calculated with BMD		
	10 year probability	HR	95% CI	10 year probability	HR	95% CI
10th	9.0%	0.77	0.68–0.87	11.5%	0.70	0.58–0.84
25th	12.6%	0.78	0.70–0.88	16.0%	0.72	0.62–0.85
50th	18.3%	0.82	0.73–0.91	22.2%	0.76	0.67–0.87
75th	26.0%	0.86	0.74–0.99	30.2%	0.82	0.82–0.93
90th	33.5%	0.90	0.74–1.10	39.8%	0.88	0.88–1.04

Table 6 Hazard ratio between treatments (strontium ranelate versus placebo) for hip fracture and for clinical vertebral fracture at different percentiles of 10 year probability (%) of a major osteoporotic fracture calculated with BMD

Percentile	Hip fracture			Clinical vertebral fracture		
	10 year probability	HR	95% CI	10 year probability	HR	95% CI
10th	11.5%	1.03	0.63–1.69	11.5%	0.65	0.49–0.88
25th	16.0%	1.01	0.66–1.54	16.0%	0.68	0.53–0.87
50th	22.2%	0.98	0.70–1.38	22.2%	0.71	0.57–0.88
75th	30.2%	0.95	0.70–1.28	30.2%	0.76	0.62–0.92
90th	39.8%	0.90	0.62–1.31	39.8%	0.81	0.64–1.03